Cellectis to present development update for eti-cel at ASH 2025

Cellectis (CLLS) announced the acceptance of two abstracts for poster presentation at the American Society of Hematology, ASH, 2025 annual meeting taking place from December 6 to 9, 2025, in Orlando, FL. The first poster provides a development update on eti-cel product candidate, an allogeneic dual CAR-T targeting CD20 and CD22 being developed in Phase 1 of the NATHALI-01 clinical trial, for patients with relapsed/refractory non Hodgkin lymphoma. In addition, the poster outlines the addition of low dose interleukin-2 to further deepen and extend anti-tumor activity of eti-cel in patients with r/r NHL, supported by compelling preclinical data. Cellectis unveiled preliminary results on eti-cel, which demonstrate an encouraging overall response rate, ORR, of 86% and a complete response, CR, rate of 57% at the current dose level, with 4 out of 7 patients achieving a complete response. The preliminary high rate of complete responses underscores the potential of this innovative approach to transform outcomes for r/r NHL patients. Cellectis expects to present the full Phase 1 dataset for eti-cel, including low-dose IL-2 combination cohorts, in 2026.